DiaMedica Therapeutics Inc.
http://www.diamedica.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From DiaMedica Therapeutics Inc.
Chinese RNA Therapy Developers Extend Fundraising Streak Into December
In the latest venture capital and private equity funding deals in China, SanegeneBio, Argo Biopharma and Ausper Biopharma raised a combined $136m on the back of their early-stage small interfering RNA and antisense oligonucleotide assets.
Chinese Gene And Cell Therapy, mRNA Developers Raise More Funds In March
Roughly $130m was raised in eight biopharma financings in China over the past months that were backed by venture capital investors.
Tech Transfer Roundup: Tiba And CEPI Strategize Together On ‘Disease X’
Immix collaborates with Israeli research institutions on BCMA-targeted CAR-T therapy. NeoImmuneTech/NIAID alliance could pave way for “animal rule” approval in acute radiation syndrome.
Medtech 100: Big Three Companies Lead From The Front With Medtech Back On Solid Growth Footing
Abbott Laboratories and Johnson & Johnson joined Medtronic in putting a clear distance between themselves and other global medtechs in the Top 10 by revenues for 2021. Post-COVID-19 procedure growth, and, for Abbott, a strong rebound in non-COVID diagnostic demand, were key drivers.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
- Other Names / Subsidiaries
-
- Sanomune Inc.
- DiaMedica Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice